Prot #ALN-TTRSC-004: ENDEAVOR: A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC

Project: Research project

Project Details

StatusFinished
Effective start/end date8/27/15 → 8/27/18

Funding

  • Alnylam Pharmaceuticals, Inc. (ALN-TTRSC-004)